Palmitoylation of human FasL modulates its cell death-inducing function by Guardiola-Serrano, F et al.
Palmitoylation of human FasL modulates its cell
death-inducing function
F Guardiola-Serrano
1,6, A Rossin
1, N Cahuzac
1,7,KL u ¨ckerath
2, I Melzer
2, S Mailfert
3,4,5, D Marguet
3,4,5,MZ o ¨rnig
2 and A-O Hueber*
,1
Fas ligand(FasL) is a transmembrane protein that regulates cell death inFas-bearing cells. FasL-mediated cell death is essential
for immune system homeostasis and the elimination of viral or transformed cells. Because of its potent cytotoxic activity, FasL
expression at the cell surface is tightly regulated, for example, via processing by ADAM10 and SPPL2a generating soluble FasL
and the intracellular fragments APL (ADAM10-processed FasL form) and SPA (SPPL2a-processed APL). In this study, we report
that FasL processing by ADAM10 counteracts Fas-mediated cell death and is strictly regulated by membrane localization,
interactions and modiﬁcations of FasL. According to our observations, FasL processing occurs preferentially within cholesterol
and sphingolipid-rich nanodomains (rafts) where efﬁcient Fas–FasL contact occurs, Fas receptor and FasL interaction is also
required for efﬁcient FasL processing, and FasL palmitoylation, which occurs within its transmembrane domain, is critical for
efﬁcient FasL-mediated killing and FasL processing.
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FasL(Fasligand)isatransmembraneproteinbelongingtothe
TNFfamily,which,uponbindingtotheFasreceptor,mediates
celldeath inFas-expressing cells.
1Invivo,FasLexpressionis
mainly detected in hematopoietic cells where it has a key role
in the induction of cell death by mediating the activation-
induced cell death of T lymphocytes, therefore contributing to
the cytotoxic effector function of T and NK cells.
2 Moreover,
FasL signaling has been reported to be critical in both the
maintenance of immune privilege and the establishment of
tumor survival.
3,4 The latter role has prompted the establish-
ment of the controversial ‘tumor counterattack’ model, which
suggests that FasL expression by tumor cells would kill Fas-
sensitive effector cells of the immune system.
5,6
In addition to its pro-apoptotic activity, FasL has been
implicated in retrograde signal transduction within FasL-
expressing cells, also called reverse signaling, which is
thought to be important in the modulation of T-cell activation.
Humans and mice, with deleterious mutations in Fas or FasL,
develop a severe lymphoaccumulative disease with an
accumulation of aberrant T-cell population, leading to
lymphadenopathy, splenomegaly and lupus erythematosus.
While Fas is expressed by several tissues, the expression of
FasL is tightly regulated at both transcriptional and post-
transcriptional levels to avoid undesirable cell death. The latter
include FasL storage in intracellular compartments,
7recruitment
into cholesterol- and sphingolipid-rich nanodomains (rafts),
8,9
and FasL proteolysis by matrix metalloproteinases (MMPs) and
the intramembrane protease SPPL2a.
10,11
We and others have previously reported that the sequential
processing of FasL by ADAM10 and SPPL2a generates
soluble extracellular FasL (sFasL), a membrane-anchored
17kDa APL fragment
10,11 and the intracellular 11kDa SPPL2a
cleavage product SPA.
10 Although several reports have
suggested that sFasL is less cytotoxic than the membrane-
boundformofFasL,
12,13arecentstudyclearlydemonstratedin
vivo that only the membrane-anchored FasL can efﬁciently
induce cell death,
14 thus highlighting the importance of FasL
processing by ADAM10 and SPPL2a in the control of Fas-
mediated cell death. Nevertheless, the molecular events that
regulate FasL proteolysis have not been addressed.
We have demonstrated that the partitioning of both FasL
and Fas into rafts is necessary for efﬁcient cell death
transduction. However, both the regulation of FasL targeting
into the rafts and the importance of this localization for FasL
proteolytic processing remain unclear.
In the present study, we show that processing of hFasL
by ADAM10, but not by SPPL2a, counteracts FasL-mediated
apoptosis. Conﬁnement of proteins into rafts can be
mediated by palmitoylation, that is, the reversible addition of
a palmitate moiety into cysteine residues. In this study,
we establish that hFasL, like its receptor Fas, is palmitoy-
lated. More importantly, we demonstrate that parti-
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palmitoylation are all essential events for hFasL proteolysis
and function.
Results
hFasL processing by metalloproteases, but not by
SPPL2a, reduces hFasL-induced cell death. We ﬁrst
aimed at studying the importance of sequential hFasL
shedding for the pro-apoptotic function of hFasL. For this
purpose, hFasL cleavage in WSU B cells stably transfected
with hFasL was prevented by using the SPPL2a inhibitor
(Z-LL)2 or the MMP inhibitor TAPI-2, and cells were co-
cultured with Fas-expressing JH6.2 Jurkat target cells. We
found that the killing capacity of hFasL was unaffected upon
inhibition of the intramembrane protease SPPL2a by (Z-LL)2
(Figure 1a), but was increased after inhibition of metallo-
proteases (Figure 1b). Sufﬁcient inhibition of hFasL cleavage
was conﬁrmed by western blot analysis of lysates prepared
from (Z-LL)2- and TAPI-2-treated WSU hFasL cells. These
data indicate that Fas-mediated cell death is regulated by
ADAM10-processing of hFasL, which may function to hinder
the pro-apoptotic function of hFasL.
Optimal processing by ADAM10 requires hFasL
localization into rafts and binding to the Fas receptor. To
test the consequences of raft localization on hFasL processing,
we performed a cholesterol oxidase treatment, which partially
inhibits lipid nanodomain formation by converting cholesterol to
cholestenone. The distribution of full-length FasL and APL in
rafts were then analyzed using a biochemical approach. Post-
nuclear supernatants (PNSs) were solubilized by polyoxy-
ethylene ether Brij 98, and lysates were subjected to
ultracentrifugation through a sucrose gradient. The various
fractions were analyzed by western blotting. The membrane
was probed with antibodies recognizing the raft protein marker
Fyn and the non-raft marker Rab5a, as a control for proper
separation. Our data show that whereas full-length FasL is only
partially located in the raft fractions, the APL fragment was
exclusively found there. In addition, the cholesterol oxidase
treatment decreased the shedding of hFasL, thereby indicating
that raft localization has a crucial role in ADAM10 processing of
hFasL (Figure 2a).
We also aimed at determining whether binding of hFasL to
the Fas receptor is required for hFasL cleavage. The point
mutation A247E in the Fas receptor-binding domain prevents
interaction of hFasL with its receptor thereby preventing
cell-mediated apoptosis (Supplementary Figure 1A and
Del-Rey et al.
24). Lysates prepared from hFasLA247E-
transfected WSU cells showed decreased levels of the APL
fragment compared with cells transfected with wild-type
hFasL (Figure 2b). Similarly, transient transfection of Fas
receptor targeting siRNA in HEK293 cells dramatically
decreased the amount of APL (Supplementary Figure 1B).
Collectively, these data demonstrate that binding to the Fas
receptor is required for the processing of hFasL by ADAM10.
ADAM10 processing of hFasL occurs within rafts. It has
been shown that differential nanodomain localization of
target protein and metalloprotease can regulate the proteo-
lytic processing.
18,19 Moreover, the above results indicate
that hFasL processing mainly occurs within rafts. To obtain
further evidence for this hypothesis, we treated hFasL-
transfected WSU cells with the metalloprotease inhibitors
TAPI-2, GI254023X or INCB-3619. Biochemical raft analysis
showed that inhibition of ADAM10-mediated proteolysis of
hFasL decreased APL production, while simultaneously
increased the amount of full-length FasL preferentially
inside the raft fractions (Figure 2c). Thus, our results sup-
port the notion that hFasL proteolysis by ADAM10 occurs
within raft nanodomains.
Palmitoylation of hFasL is required for efﬁcient
processing by ADAM10 and for FasL-induced cell
death. Protein palmitoylation represents one of the raft
targeting signals. Using acyl biotinyl-exchange chemistry, we
show that hFasL is indeed palmitoylated. Incorporation of
point-mutated hFasL revealed that this post-translational
modiﬁcation occurs at the cysteine position 82, which is
located at the N-terminal portion of the transmembrane
domain (Figures 3a and b).
To investigate whether binding to the receptor is necessary
for hFasL palmitoylation, we tested the palmitoylation status
of the hFasLA247E mutant. Our results showed that this
Ezrin
APL
FL
FasL
SPA
-
G247
Ab-3
Tapi 2
Tapi 2
%
 
C
e
l
l
 
d
e
a
t
h WSU hFasL
WSU
10
20
30
40
50
60
%
 
C
e
l
l
 
d
e
a
t
h
(Z-LL)2
10
20
30
40
50
60
WSU hFasL
WSU
- (Z-LL)2
Ezrin
APL
FL
FasL
SPA
G247
Ab-3
-+
-+
+
+
Figure 1 Metalloprotease, but not SPPL2a-mediated, FasL processing
decreases FasL-induced cell death. WSU cells were pre-treated with inhibitors
of either MMP or SPPL2a before co-culture with the Fas-bearing JH6.2 cells
(inhibitors remained in media during the co-culture period). Effective inhibition of
ADAM10 or SPPL2 was conﬁrmed by western blot. G247 antibody was used to
detect the full-length FasL and the antibody Ab-3 was employed for the detection of
the N-terminal APL and SPA fragments, ezrin was used as loading control. Cell
death was quantiﬁed by ﬂow cytometric quantiﬁcation of the subG1 population of
propidium iodide-stained ethanol-ﬁxed cells. (a) JH6.2 cells were co-cultured for
6 hours with WSU cells stably transfected with either hFasL or mock transfected,
and were either pre-treated with the SPPL2 inhibitor (Z-LL)2 (2mM, 2h) or left
untreated. The graph represents the average of two independent experiments, with
error bars indicating theS.D.(b)JH6.2 cellswere co-cultured for 4h with WSU cells
stably transfected with hFasL or mock transfected and either pre-treated with the
MMP inhibitor TAPI-2 (50mM, 2h) or left untreated. The graph represents the
average of four independent experiments, with error bars indicating the S.D.
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Cell Death and Diseasemutant, which is unable to bind to Fas, was also palmitoylated
(Figure 3b). Therefore, palmitoylation of hFasL in the
transmembrane domain at cysteine residue 82 does not
require binding to Fas receptor.
We then assessed whether hFasL palmitoylation is
important for Fas-mediated cell death. We generated WSU
cells stably expressing comparable levels of wild-type hFasL
orhFasLC82Satthecellsurface(Figure3c,inset).Co-culture
experiments with Fas-expressing JH6.2 target cells revealed
that the killing capacity of the hFasLC82S mutant was
signiﬁcantlylower than that ofthe wild-type hFasL (Figure 3c).
Next, we investigated the proteolysis of the palmitoylation-
deﬁcient mutant. Immunoblot analysis of WSU cells stably
expressing wild-type hFasL or hFasLC82S revealed that less
APL was produced by ADAM10 cleavage of the hFasLC82S
mutant compared with wild-type hFasL (Figure 3d). In
addition, WSU cells transfected with wild-type hFasL and
treated with the general palmitoylation inhibitor 2-bromopal-
mitate produced decreased amounts of APL compared
with untreated cells (Supplementary Figure 1C). Similar to
the decreased APL production, signiﬁcantly lower level of
soluble FasL was found in the supernatant of the hFasLC82S
mutant cells compared with wild-type hFasL-expressing
cells (Figure 3e). Taken together, our data indicate that
palmitoylation of hFasL occurs upstream of Fasreceptorbinding
and is a pre-requisite for efﬁcient cleavage by ADAM10.
Neither FasL palmitoylation and nor FasR binding are
required for the interaction of hFasL with ADAM10. The
ADAM10 pro-form is processed and thereby converted to the
mature form of the molecule by the pro-protein convertases
furin or PC7. To investigate the nature of the ADAM10 forms
interacting with hFasL and the location of this functional
interaction, we analyzed the distribution of ADAM10 inside
and outside the rafts. Biochemical analysis revealed that the
pro-form of ADAM10 was excluded from rafts, whereas the
mature form was localized within and outside the raft fractions
(Figure 4a). Therefore, conﬁnement of active ADAM10 does
not restrict the interaction to any nanodomain while the
interaction with the pro-form is restricted to the non-raft fraction.
To ﬁnd out whether FasL palmitoylation affects the
interaction of hFasL with ADAM10, lysates from WSU cells
stably transfected with hFasL, hFasLC82S or hFasLA247E
were subjected to immunoprecipitation with an anti-ADAM10
antibody. Figure 4b shows that FasL interacts with the
pro-form of ADAM10 regardless of its palmitoylation status.
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Figure 2 hFasL processing depends on the lipid nanodomainintegrity and on the binding to Fas receptor. (a)S t a b l eW S U - hFasL cells were treated with cholesterol oxidase
(CO; 4U/ml) for 4h or left untreated (NT). Cells were then solubilized in Brij 98 detergent and subjected to sucrose gradient separation before analysis of the heavy fraction (HF)
and the light fraction (LF)bywestern blot analysis.(b) Cell lysatesofWSU cellsstablytransfected with wild-type hFasL orhFasLA247E were analyzed bywestern blotting.G247
antibody was used to detect the full-length FasL and the antibody Ab-3 was used to measure the N-terminal APL fragment; Ezrin was used as loading control. (c)S t a b l eW S U
hFasLcellsweretreatedwiththemetalloproteaseinhibitorsTAPI-2(50mM),GI254023x(10mM)orINCB-3619(10mM)for4horleftuntreated(NT).Cellswerethensolubilizedin
Brij 98 detergent and subjected to sucrose gradient separation before western blot analysis of the heavy and light fractions (identiﬁed respectively by Rab5 and Fyn). G247
antibody was used to detect the full-length FasL and the antibody Ab-3 was used to detect the N-terminal APL fragment. Ezrin was used as loading control
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Cell Death and DiseaseWe also observed an increase in ADAM10 binding to
hFasLA247E, indicating that this interaction occurs before
binding of FasL to its receptor (Figure 4b).
To study the importance of the hFasL interaction with the
ADAM10 pro-form in further detail, we treated the cells with
the MMP inhibitor TAPI-2 or with the furin inhibitor decanoyl-
Arg-Val-Lys-Arg-chlorometylketone (Dec-CMK). Both treat-
ments reduced the amount of cleaved APL fragment and the
production of soluble FasL (Figures 4c and d), indicating that
the interaction with the ADAM10 pro-form is important for the
hFasL cleavage.
WealsoanalyzedtheinteractionofADAM10withhFasLinthe
presence of these inhibitors. Both treatments led to increased
amounts of the FasL co-immunoprecipitated with ADAM10
(Figure 4e). Our results indicate that the interaction with the
ADAM10 pro-form is important for the production of APL.
Palmitoylation and receptor interaction alter the
nanodomain localization of hFasL. We have previously
demonstrated that the localization of hFasL within rafts is
essential for maximum induction of cell death.
8 In light of
these ﬁndings, we investigated whether both palmitoylation
and receptor binding are required for hFasL raft localization.
To monitor hFasL localization of the wild-type FasL and its
mutants, we investigated the in vivo lateral diffusion of
hFasL-GFP, hFasLA247E-GFP and hFasLC82S-GFP using
ﬂuorescence correlation spectroscopy (FCS). FCS measures
the apparent diffusion time of molecules, providing infor-
mation on the diffusion mode of the molecule of interest. On
the basis of diffusion law,
20 the diffusion time of a protein (td,
the average time a molecule stays within an illuminated area)
can be plotted versus the square of the beam radius (w
2),
and from this representation, the intercept to the y axis can
be calculated (t0). The t0 value is indicative of the molecular
conﬁnement mode and is positive in the case of conﬁnement
to nanodomains, negative in the case of trapping in a
meshwork and zero if the molecule is neither conﬁned within
discrete domains nor hindered by a network. We have
previously reported that wild-type hFasL fused to GFP exhibi-
ted a diffusion behavior corresponding to a conﬁnement
inside rafts.
8 For wild-type FasL, t0 was determined as 35.9±
8.5ms, a diffusion behavior comparable to the raft marker
BODIPY-C5-ganglioside-GM1 (25±3 (Lenne et al.
21)). In
contrast, the palmitoylation-deﬁcient mutant hFasLC82S and
the receptor-binding mutant hFasLA247E displayed a
signiﬁcantly different diffusion behavior, reﬂected by reduced
t0 values (8.4±2.9 and 6.2±4.7, respectively), indicating a
lower conﬁnement of the proteins into nanodomains (Figure 5).
The effective diffusion coefﬁcient (Deff), deﬁned by the
inverse of the diffusion law slope, represents the long-range
diffusion of the proteins of interest. Deff was dramatically
decreased for the hFasLA247E receptor-binding mutant
(0.29±0.02versus0.54±0.17mm
2/sforwthFasL),indicating
a greatly reduced long-range diffusion of hFasLA247E.
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Figure 3 Palmitoylation of hFasL is required for optimal hFasL processing and cytotoxic activity. (a) Diagram of the hFasL transmembrane domain, highlighting the
proposed palmitoylation site at aa 82, which we mutated to serine. (b) WSU cells stably transfected with constructs encoding for hFasL, hFasLC82S or hFasLA247E were
subjected to an acyl-biotinyl exchange protocol as described in Materials and Methods. Speciﬁcity of the experiment was controlled by omitting the hydroxylamine (HA)
treatment and Fyn was used as an internal control for reaction efﬁciency. (c) JH6.2 cells were co-cultured for the indicated time points with WSU cells stably transfected with
hFasL, hFasLC82S or mock. Cell death was then quantiﬁed by ﬂow cytometric analysis of the subG1 population of propidium iodide-stained ethanol-ﬁxed cells. The graph
representstheaverageoffourindependentexperimentswitherrorbarsindicatingtheS.D.Thelevelofexpressionofwild-typehFasLorhFasLC82SatthecellsurfaceofWSU
transfected cells was comparable (see the inset). (d) Cell lysates of WSU cells stably transfected with constructs encoding for hFasL, hFasLC82S or mock transfected were
analyzed by western blotting. (e) Levels of soluble FasL were measured in the supernatant of WSU cells stably transfected with wild-type hFasL or hFasLC82S. The graph
represents the average of two independent experiments with error bars indicating the S.D.
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Cell Death and DiseaseDiscussion
Our results demonstrate that shedding of hFasL by ADAM10
counteracts the cytotoxic activity of hFasL. In this study, we
show that ADAM10 processing of hFasL depends on the
integrity of the cholesterol- and sphingolipid-enriched nano-
domains (rafts) and on the interaction with the Fas receptor.
Finally, we have reported the ﬁrst description of hFasL
palmitoylation. This post-translational modiﬁcation is required
for appropriate partitioning of hFasL into rafts, for efﬁcient
Fas-mediated cell death and hFasL processing by ADAM10
(Figure 6).
Data from other groups substantiate our observations
that metalloprotease inhibition decreases hFasL processing
and increases its killing activity.
11 The increased cytotoxicity
of hFasL may depend either on the accumulation of the full-
length FasL form or on the decrease in the proteolysis
products,namelysFasL,APLandSPA.Ourresultsclarifythat
neither APL nor SPA has an effect on hFasL-induced cell
death or on hFasL processing. The decrease in hFasL
cytotoxicity is likely due to the reduced amount of full-length
FasL and/or the production of soluble FasL. It is possible that
sFasL may compete with the full-length form for binding to the
Fas receptor. It also remains unclear whether sFasL proteins
are exclusively produced by processing of full-length hFasL at
the plasma membrane. Overall, the role of hFasL processing
by ADAM10 might be a down-modulation or termination of the
deathsignal,ashasbeendescribedforsheddingofreceptors,
such as TNFR1 following its engagement,
22 protection of
the neighboring cells by soluble FasL
23 or reverse signaling
into the ligand-bearing cells, mediated by the liberated
SPA fragment.
We demonstrated that FasL interaction with its receptor
Fas is necessary for FasL processing. The A247E mutation
located within the receptor-binding site, which causes
reduced killing of target cells (Supplementary Figure S1A
and Del-Rey et al.
24), displays reduced FasL processing.
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Figure 4 Palmitoylation of hFasL and receptor-binding are not required for hFasL-ADAM10 interaction. (a) ADAM10 is localized both inside and outside the rafts’
nanodomains. Cells were solubilized in Brij 98 detergent and subjected to sucrose gradient separation before immunoblot analysis of the heavy fraction (HF) and the light
fraction(LF) to detect the differentforms of hFasL and ADAM10.(b) Co-immunoprecipitation of hFasL with ADAM10.Cell lysatesprepared fromWSU cells stablytransfected
with hFasL, hFasLC82S, hFasLA247E or mock were subjected to immunoprecipitation using an anti-ADAM10 antibody and were analyzed by western blot. (c) Stable WSU-
hFasL cells were treated with TAPI-2 (50mM) or Dec-CMK (5mM, 15mM) for 4 hours or left untreated (NT) before cell lysates were analyzed by western blot. (d) Levels of
sFasL in the supernatant of cells treated with TAPI-2 (50mM) or Dec-CMK (15mM) for 4 hours or left untreated (NT) were quantiﬁed by ELISA. (e) Stable WSU-hFasL cells
were either treated for 4h with TAPI-2 (50mM) or Dec-CMK (15mM), or left untreated (NT) before cell lysates were subjected to immunoprecipitation using an anti-ADAM10
antibody and were analyzed by western blot
Figure 5 Wild-type hFasL is conﬁned to nanodomains whereas the
palmitoylation- and receptor-deﬁcient mutants are not. Diffusion behavior of
hFasL-GFP, hFasLC82S-GFP and hFasLA247E-GFP in COS-7 cells was
measured by FCS at 371C; t0 was determined from the position at which the
diffusion curves intersect the time axis (diffusion time). Error bars indicate the S.D.
of 10 independent experiments
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Cell Death and DiseasehFasL processing following its interaction with Fas would
restrict hFasL cytotoxicity to the target cell and avoid
excessive cell death. Several ligands and receptors are
processed upon binding by their partner, such as the Notch
receptor which is cleaved after activation by its ligand Delta
(reviewed by Kopan
25 and Weinmaster
26) and the Ephrin2
ligand, which is processed once it binds to its receptor
Eph3A.
27 Proteolysis can also be promoted by cross-talk with
other receptors. Examples include shedding of the Ephrin
ligand which is stimulated by recruitment of G proteins
28 and
shedding of CD44 which can occur after binding to small
hyaluronan oligosaccharides
29 or by EGF stimulation through
activation of Rac GTPases.
30 It remains an open question
whether and how other receptors might affect the processing
of hFasL. Using the hFasLA247E mutant, which is excluded
from rafts, we demonstrated that hFasL recruitment by the
Fas receptor is important for its localization into these
nanodomains. This hypothesis is further corroborated by our
previously published data showing that interaction of hFasL
with Fas increases FasL localization inside rafts.
8
We then demonstrate that although hFasL and ADAM10
display a similar distribution inside and outside rafts, FasL
processing depends on the integrity of the raft domains.
Indeed, this result also explains the decreased processing
capacity of the receptor-binding mutant hFasLA247E. Indivi-
dual rafts are relatively small and display heterogeneous
protein content. This heterogeneity allows regulation of
protein activity owing to differential raft localization.
31,32 In
contrast to FasL/ADAM10, differential nanodomain localiza-
tion of the target protein and the metalloprotease responsible
for its cleavage has been reported for other molecules.
In these cases, this differential protein localization might
controlmoleculeprocessing.Thisstrategyhasbeenobserved
for the CD30 protein which is located in rafts, whereas the
metalloprotease responsible for its shedding, ADAM17, is
excluded.
18 In the case of the amyloid precursor protein, the
presence of two distinctpools distributed inside and outside of
rafts results in differential processing.
19
FasL is capable of binding to ADAM10 before interaction
with the Fas receptor, and according to our results, this early
binding event occurs outside rafts and is important for the
proteolysis of hFasL. In this FasL population, hFasL proteo-
lysis is activated by a cleavage of the ADAM10 pro-form by
Furin. We cannot exclude the possibility that the FasL
cleavage might also occur by direct interaction with the active
form of ADAM10. We have yet to determine whether binding
to ADAM10 outside rafts is important for FasL processing at
the plasma membrane or for intracellular processing. In
general, recruitment of ADAM10 to a receptor–ligand system
following ligand binding of the receptor EphA3 has also been
described. ADAM10 then cleaves the ligand Ephrin 5 in
trans.
33 Interaction with additional unidentiﬁed proteins might
also be essential for processing of hFasL by ADAM10 as, for
example, recruitment of tetraspanins by ADAM10 has been
reportedtoincreasecleavageofADAM10substrates
34and/or
proteolytic maturation of ADAM10.
35
We have previously shown that the death receptors Fas
36
and DR4
37 are palmitoylated. This modiﬁcation is necessary
for receptor partitioning into rafts and for receptor engage-
ment. We demonstrated in this study that FasL palmitoylation
A10
APL
FasL
sFasL
Fas
A10
FasL
Killer cell
Target cell
Cell death
Palmitoylation
Figure 6 Schematic representation of the ADAM10-mediated processing mechanism of hFasL. At leat two different populations of hFasL were found in our study, one
being inside the rafts, the other outside the rafts. Both population can interact with ADAM10, but only the palmitoylated raft localized one might optimally interacts with the
receptor and mediates Fas-cell death. Only in this population FasL can be processed; a procedure which downregulates Fas-mediated cell death on the target cell
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might represent an extended modiﬁcation for efﬁcient inter-
action and recruitment. However, palmitoylation of both
components is not always necessary, as exempliﬁed by
TNF-a, where TNF-a is palmitoylated,
38 but its receptor
TNFR1
37 remains unmodiﬁed.
Our data imply that palmitoylation of hFasL is important for
its biological function, as mutation of the palmitoylation site
decreases the level of hFasL-induced cell death. As with the
receptor-binding mutant hFasLA247E, the hFasL palmitoy-
lationmutantalsoexhibitsdecreasedproteolysisbyADAM10.
Fluorescence correlation spectroscopy suggests that locali-
zation of both the palmitoylation and the receptor-binding
mutants is not conﬁned to raft nanodomains, in contrast to the
wild-type hFasL. This delocalization would explain the
observed decrease in FasL-mediated cell death and proteo-
lytic cleavage.
39
Insummary,hFasL proteolysisbyADAM10dependsonthe
interaction of the ligand with its receptor Fas, and the integrity
of the raft nanodomains. Post-translational modiﬁcations,
suchaspalmitoylation,whichchangethepartitioningofhFasL
into rafts, might enable the cell to ﬁne-tune the processing of
hFasL by ADAM10 and, consequently, hFasL-mediated cell
death.
Materials and Methods
Antibodies and reagents. The antibodies used for immunoblotting were as
follows: anti-ADAM10 (Chemicon/Millipore, Billerica, MA, USA), anti-Ezrin (Zymed
laboratories, San Francisco, CA, USA), anti-FasL clone G247-4 (BD PharMingen,
San Diego, CA, USA, referred to as G247 in the manuscript), anti-FasL clone Ab-3
(Calbiochem/Merck Chemicals, Nottingham, UK, referred to as Ab-3 in the
manuscript), anti-FLAG (M2, Sigma), anti-Fyn (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-Rab5 (Santa Cruz Biotechnology) and horseradish
peroxidase-conjugated anti-rabbit and anti-mouse antibodies (Jackson
ImmunoResearch, West Grove, PA, USA). The anti-FasL antibody clone BR-17
(Diaclone, Besanc ¸on, France) was used for the expression analysis by ﬂow
cytometry. The matrix metalloprotease inhibitor TAPI-2 (N-(R)-(2-(hydroxyamino-
arbonyl)methyl)-4-methylpenthanoyl-L-t-butyl-alanyl-L-alanine, 2-aminoethyl amide)
was purchased from Merck (Nottingham, UK). The ADAM10 inhibitor GI254023X
((2R, 3S)-3-(formyl-hydroxyamino)-2-(3-phenyl-1-propyl) butanoic acid ((1S)-2,2-
dimethyl-1-methylcar-bamoyl-1-propyl) amide) has been described elsewhere.
15
The small molecule protease inhibitor INCB-3619 obtained from P. Scherle (Incyte
Corporation, Wilmington, DE, USA) was previously described.
16 Furin convertase
inhibitor Dec-CMK was purchased from Alexis (Lausen, Switzerland).
Cell culture and transfection procedures. WSU and JH6.2 cells were
cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum at 371C in a 5% CO2 atmosphere. HEK293 and HEK293
Tcells(ATCC no.CRL-1653) wereculturedin Dulbecco’sModiﬁedEagle’sMedium
(Invitrogen),supplementedwith10%FBSat371Cina5%CO2atmosphere.COS-7
cells (ATCC no. CRL-1657) were grown in DMEM supplemented with 10% FBS,
glutamine (2mM) at 371C in a 5% CO2 atmosphere.
WSU cells stably expressing hFasL or hFasLC82S were established by
transfection with pCR33 hFasL, pCR33 hFasLC82S and pCR33 hFasLA247E
constructs using an ECM830 BTX electro square porator (Genotronics, Landgraaf,
The Netherlands) at 200V, 60ms and 1 pulse, and selected by supplementing the
growth medium with 1mg/ml Geneticin (Gibco/Invitrogen, Carlsbad, CA, USA) 24h
after transfection. HEK293 cells were transiently transfected using calcium
phosphate precipitation in 10cm culture dishes. Transient transfection of COS-7
cells was performed with ExGen 500 (Euromedex, Souffelweyersheim, France).
Constructs. N-terminal FLAG-tagged human FasL was ampliﬁed by PCR from a
plasmid template and was cloned into the mammalian expression vector pCR33
(kindly provided by Dr. Hermann Eibel, Freiburg, Germany), resulting in pCR33
hFasL.T h epCR33 hFasLC82S/pCR33 hFasLA247E constructs were generated
using the Quikchange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA),
withpCR33FasLasatemplate.ToproducetheN-terminalGFP-tag,FasLcDNAwas
clonedintothepEGFPC1vectorfromClontech(MountainView,CA,USA)resultingin
pCR33 GFP-FasL.T h eGFP-hFasLC82S and GFP-hFasLA247E constructs were
obtained using the Quikchange site-directed mutagenesis kit, with pCR33 GFP-FasL
as a template. Primers utilized are listed in the supplementary materials.
Protein palmitoylation. Protein palmitoylation was determined with an
adapted acyl-biotinyl exchange protocol from Drisdel and Green,
17 which is
comprised of the following three steps. Cell lysates were prepared in 250mM
HEPES, 1mM EDTA and 2.5% SDS, and incubated with 0.1% methyl
methanethiosulfonate (Sigma, St Louis, MO, USA) at 501C for 20min to block the
free thiols. Proteins were subsequently precipitated with acetone and resuspended in
1M hydroxylamine pH 7.4 (Sigma) to speciﬁcally release thioester-linked palmitoyl
moietiesandrestorethemodiﬁedcysteinestothiols.Theproteinsuspensionwasthen
mixed with 0.2mM biotin-HPDP (Pierce/Thermo Scientiﬁc, Rockford, IL, USA) for
1h at room temperature. Biotinylated proteins were puriﬁed with neutravidin
beads (Pierce/Thermo Scientiﬁc), separated by SDS-PAGE and submitted to
immunoblottingusinganantibody-recognizingFasL.Speciﬁcityoftheexperimentwas
controlled by omitting the hydroxylamine treatment.
Cell death assays. The killing potential of FasL-expressing cells was
determined using co-culture assays with Fas-expressing target cells (JH6.2) at a
killer-to-target ratio of 1:1. Target cells were pre-stained with 5mM diacetate
succinimidyl ester (CFSE, Molecular Probes/Invitrogen, Carlsbad, CA, USA) before
co-culturing to distinguish them from killer cells during FACS analysis. The
quantiﬁcationofapoptosisinthetargetcellswasperformedbyﬂowcytometry.Brieﬂy,
cellswereﬁxedwithice-cold70%ethanol,washedwith38mMsodiumcitrate(pH7.0)
and stained for 20min at 371Cw i t h6 9mM propidium iodide (Sigma)/38mM sodium
citrate/5mg per ml RNaseA (Sigma). Cells were subsequently analyzed by ﬂow
cytometry(FACSCalibur;BectonDickinson,FranklinLakes,NJ,USA).Theproportion
of apoptotic cells was determined as represented by the subG1 peak.
Separation of detergent-resistant membranes. PNS from 20 10
6
WSU cells was solubilized in 1ml buffer A (25mM HEPES, 150mM NaCl, 1mM
EGTA, 10mM sodium pyrophosphate, 10mM sodium ﬂoride, 5mM orthovanadate,
protease inhibitor cocktail) containing 1% Brij 98 (Aldrich, St Louis, MO, USA) and
10% glycerol for 1h on ice, followed by the addition of 2ml of 2M sucrose in buffer
A, before being placed at the bottom of a step sucrose gradient (1.33-0.9-0.8-0.75-
0.7-0.6-0.5-0.4-0.2M) in buffer A. The gradient was centrifuged at 250000 g for
16h in an SW41 Beckman rotor (Beckman Instruments, Gagny, France) at 41C.
One-milliliter fractions were harvested from the top, except for the last fraction that
contained 3ml.
Fluorescence correlation spectroscopy experiments. Fluorescence
correlation spectroscopy (FCS) measurements were performed with a custom
a p p a r a t u sa sp r e v i o u s l yd escribed. Brieﬂy, FCS data were collected using a
confocal-based microscope (Axiovert 200M; Zeiss, Oberhocken, Germany) equipped
with an Aprochromat 40 /1.2 numeric aperture water-immersion objective and
e x c i t a t i o nf r o ma4 8 8 - n ml i n eo fa nA r
þ ion laser. The laser waist was set by selecting
the lateral extension of laser beam falling into the back aperture of the objective with a
diaphragm. Fluorescence was collected through a 525 to 565-nm bandpass ﬁlter.
A confocal pinhole reduced the out-of-focus ﬂuorescence. FCS measurements were
carried out in Hanks balanced salt solution with 10mM HEPES, pH 7.4, by illuminating
t h es a m p l ew i t ha ne x c i t a t i o np o w e ro f3mW at the back aperture of the objective lens.
Autocorrelations were processed by a hardware correlator (http://www.correlator.com,
Hong Kong) and data were analyzed with built-in functions of IGOR Pro (WareMetrics,
Lake Oswego, OR, USA).
Immunoprecipitation. WSU cells (20 10
6) were sonicated in buffer A
(25mM HEPES, 150mM NaCl, 1mM EGTA, 10mM NaP-P, 10mM NaF, 5mM
Na3VO4,25mMb-glycerolphosphate,5mg/mlleupeptin,0.125Ua2macroglobulin,
10mg/ml pepstatinA, 10mg/ml chymostatin) containing 0.5% Nonidet P-40 (NP-40)
and 10% glycerol at 431C and then centrifuged to discard cell debris. The
supernatant was incubated overnight at 41C with 30ml Protein G sepharose beads
(Invitrogen) pre-incubated with an anti-ADAM10 antibody (Millipore). The beads
were washed four times with buffer A containing 0.5% NP-40 and 10% glycerol and
the immunoprecipitates were eluted from the beads with Laemmli buffer at 951C for
5min. Samples were separated by SDS-PAGE and analyzed by immunoblotting.
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Cell Death and DiseaseFasL-speciﬁc ELISA. The culture medium of WSU cells incubated at
10 10
6 cells per ml for 4h was harvested to analyze soluble proteins. sFasL
presentinthesupernatantwasmeasuredbyELISAusingthehumansFasLmodule
set (Bender Medsystems,Vienna, Austria). Brieﬂy, a 96-microwell plate was coated
overnight with 2.5mg/ml mouse anti-FasL capture antibody at 41C, washed with
phosphate-buffered saline (PBS)/0.05% Tween (PBS-T) and then blocked with 3%
bovine serum albumin in PBS for 2h at room temperature. After washing with
PBS-T, samples and standard were added. Next, biotinylated anti-FasL detection
antibody was applied to each well and the plate was incubated for 2h at room
temperature,washedandincubatedfor 1h at roomtemperaturewith astreptavidin-
peroxidase conjugate. The TMB super-sensitive microwell one component
peroxidase substrate (Tebu-bio, Le-Perray-en-Yvelines, France) was added and
the reaction was stopped after 20min incubation at room temperature by the
addition of 4N H2SO4 and the microwell plate was read at 450nm.
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